U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07652164) titled 'Water Vapor Ablation for Grade Group 3 Prostate Cancer' on June 11.
Brief Summary: The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer.
Participants will undergo treatment with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DEVICE: Water Vapor Ablation
Water vapor ablation delivered transurethrally in patients with Grad...